Trial Information
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo versus Phesgo after Induction Therapy with Phesgo+Taxane in Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
Sponsor: Roche Laboratories, Inc.
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
